The presence of a BRAF mutation can influence the prognosis of cancer patients. In melanoma, for example, BRAF-mutant tumors tend to be more aggressive, but the availability of targeted therapies has improved outcomes significantly. In colorectal cancer, BRAF mutations are associated with poorer prognosis, but ongoing research aims to enhance therapeutic options and improve survival rates.
